|  |  | 

India Top Headlines

Government explores possibility of Covaxin production outside India | India News


NEW DELHI: To address the shortage of Covid-19 hits in the country, the government is exploring the possibility of boosting vaccine production, including identifying manufacturing sites for locally developed Covaxin outside of India, sources said.
The government also intends to address the matter with the World Health Organization (WHO) to increase Covaxin production.
He will also discuss with Moderna, Johnson and Johnson and other vaccine manufacturers the issue of voluntary licensing to third party manufacturers in India on the basis of technology transfer.
These issues were discussed at an inter-ministerial meeting on May 18 to deliberate on options, including voluntary licensing, compulsory licensing, and government use authorization under the Patents Act of 1970, available to increase the availability of medicines and vaccines used to treat COVID. -19.
The Foreign Ministry has also been asked to take up the matter with AstraZeneca, the maker of Covishield, to encourage them to grant more voluntary licenses in India.
The MEA and the Department of Biotechnology (DBT) will also prepare a roadmap to address raw material supply constraints for Covishield and identify raw material sources, the sources said.
Regarding the Pfizer vaccine, the Department for the Promotion of Industry and Domestic Trade (DPIIT) will address the matter with MEA, Niti Aayog and the Legal Secretary to prepare a status report on the subject of the indemnity and liability agreement proposed by the manufacturer of the vaccine, they added. .
Many states have complained about vaccine shortages. To address the problem, the government has been taking steps to increase Covaxin production.
Last week, VK Paul, Member (Health) of Niti Aayog, said that Covaxin requires a Biosafety Laboratory-3, a facility that is not available to everyone.
The DBT and the Comptroller General of Drugs of India (DCGI) have been asked to identify manufacturers that have BSL-3 facilities, as well as those who may establish such a facility to increase manufacturing sites in the India, the sources said.
“(The MEA has been asked) to undertake the exercise of identifying Covaxin manufacturing sites globally in consultation with DBT. The DoHFW (Department of Health and Family Welfare) may address the matter with WHO to push forward the manufacture of Covaxin “, a source said.
The DBT has been asked to report on the incentives, including the royalty, given to Bharat Biotech for granting a license to manufacture Covaxin on the basis of technology transfer.
Last month, DBT announced a plan to significantly increase Covaxin production.
This included connecting the dots at three public sector companies: Haffkine Biopharmaceutical Corporation Ltd, Mumbai, a power supply under the Maharashtra government; Indian Immunologicals Limited (IIL), Hyderabad, a National Dairy facility; and Bharat Immunologicals and Biologicals Limited (BIBCOL), Bulandshahr, a PSU under the DBT.
Paul had said that doses of 7.5 crore are expected to be produced in August and 10 crore in September.
Last week, the DBT also said that the Gujarat Biotechnology Research Center, Gujarat Government Department of Science and Technology, together with Hester Biosciences and OmniBRx, has also stepped up their discussions with Bharat Biotech to expand Covaxin technology and produce a minimum of 20 million doses. per month.
Technology transfer agreements have been concluded with all manufacturers.
Separately, there are plans to manufacture the vaccine in Maharashtra and Karnataka.
Last week, the government estimated that by December, the country will have 216 crore of vaccines, including 75 crore from Covishield and 55 crore from Covaxin.
Additionally, Biological E is expected to produce 30 crore doses, Zydus Cadila 5 crore, Serum Institute of India 20 crore doses of Novavax and Bharat Biotech 10 crore doses of its nasal vaccine, while Gennova will make available 6 crore doses and Sputnik V 15.6 crore dose, he said.
Biological E, Zydus Cadila, Gennova, Bharat Biotech nasal vaccine vaccine candidates are in various stages of clinical trials. PLB / PR
SMN SMN 05211617 NNNN

Times of India